Hydroxyeremophilone is one of the characteristic oxygenated sesquiterpene ketones of Buddha wood oil and is the literature compound often written more systematically as 9-hydroxy-7(11),9-eremophiladien-8-one. Live sources support its registry identity, its recurring role as a major Buddha wood marker, and one isolated-compound in-vitro cytotoxicity result from the core Eremophila mitchellii phytochemistry paper. That makes hydroxyeremophilone useful as an archive chemistry marker with limited but real preclinical evidence and clear gaps around human safety or efficacy data.
Chemical identity and composition
NIST lists hydroxyeremophilone under CAS 4895-42-5 and gives the molecular formula C15H22O2. The major Buddha wood phytochemistry paper uses the equivalent name 9-hydroxy-7(11),9-eremophiladien-8-one and cites older stereochemical work on interconversion among eremophilone, hydroxyeremophilone, and hydroxydihydroeremophilone, showing that this constituent has a long structural-chemistry history but a short direct bioactivity literature.
Aroma and practical use
- Use the recorded woody, earthy, smoky, balsamic, buddha-wood-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
In the 2011 Eremophila mitchellii study, isolated hydroxyeremophilone, named there as 9-hydroxy-7(11),9-eremophiladien-8-one, showed dose-dependent cytotoxicity against P388D1 mouse lymphoblast cells with an IC50 of 105 micrograms per mL.
In the 2011 Eremophila mitchellii study, isolated hydroxyeremophilone, named there as 9-hydroxy-7(11),9-eremophiladien-8-one, showed dose-dependent cytotoxicity against P388D1 mouse lymphoblast cells with an IC50 of 105 micrograms per mL.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A publicly accessible Buddha wood GC-MS report listed hydroxyeremophilone at 25.03%, supporting its status as a major compositional marker rather than a trace constituent.
A publicly accessible Buddha wood GC-MS report listed hydroxyeremophilone at 25.03%, supporting its status as a major compositional marker rather than a trace constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific public dermal limit, phototoxicity threshold, or human safety study for isolated hydroxyeremophilone was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The available direct activity data are preclinical and should not be translated into medical claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (8)
- Direct literature on isolated hydroxyeremophilone is sparse outside Buddha wood composition work and one cytotoxicity assay.
- No public human trial, constituent-specific dermal limit, or phototoxicity review was located.
- Most accessible safety language applies to Buddha wood oil mixtures rather than the isolated molecule.
- No IFRA Standard, RIFM safety assessment, or Tisserand & Young dermal limit was found for this constituent; the previously listed 2% dermal limit was an uncited placeholder and has been removed pending real safety data.
- This record and hydroxy_eremophiladienone_9 describe the same molecule under the same CAS 4895-42-5 (confirmed via the shared NIST entry); the shared CAS is not an error but reflects duplicate archive records for one compound.
- Second-pass 2026-07-13 retry tried a direct CAS-number search (4895-42-5) against ECHA and general web sources as a different angle from the prior IFRA Standards Library search; results returned only unrelated 'hydroxy-' fragrance compound Wikipedia pages and no ECHA C&L or RIFM/IFRA entry for this CAS. No authoritative constituent-specific dermal safety source was found; fields remain null/false.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.